v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities    
Net loss $ (7,908,641) $ (2,170,810)
Adjustments to reconcile net loss to net cash used in operating activities:    
Bad debt expense 1,567
Depreciation and amortization 479,307 1,622
Finance cost 620,503
Share-based compensation 182,761 (42,996)
Straight-line rent expense 61,730 (230)
Change in fair value of derivative liabilities (701,920)
Non-cash interest expense 1,040,865 9,684
Research and development costs for intangible assets 14,358
Gain on termination of intangible asset (129,613)
Loss on the sale of Skincare 39,676
Loss on disposal of PP&E 63,345
Realized loss (gain) on sale of investments (86,392) 371,494
Unrealized loss(gain) on investments (5,322) (238,899)
Changes in operating assets and liabilities:    
Receivables and other receivables 529,958 (104,473)
Prepaid expenses and deposits (37,000) 120,999
Inventory (278,909) 22,966
Accounts payable and accrued liabilities 1,081,564 (169,268)
Customer deposits (20,496)
Due to related parties (10,790) (397,728)
Cash flows used in operating activities1 [1] (4,967,374) (2,693,714)
Investing activities    
Purchase of investments (2,870,818) (995,100)
Proceeds from sale of investments 2,883,988 1,109,921
Purchase of equipment (335,518)
Acquisition of businesses, net of cash acquired (5,846,192)
Issuance of promissory note (127,300)
Purchase of intangible assets (6,000)
Cash flows used in investing activities1 [1] (6,168,540) (18,479)
Financing activities    
Exercise of Series A warrants 1,938,772
Proceeds from the issuance of common stock and warrants 1,484,028
Share issuance costs (531,290)
Repurchase of shares and warrants (179)
Issuance of common shares under ATM agreement 1,519,437
Repayment towards promissory note (170,000)
Equipment financing proceeds 353,468
Repayment towards equipment financing (131,585)
Proceeds from the Pre-Paid Purchases of Equity Purchase Facility (“ELOC”), net 22,929,610
Proceeds from issuance of registered shares 891,507
Cash flows provided by financing activities 23,873,000 4,410,768
Effect of exchange rate changes on cash 2,339 (400)
Increase in cash 12,739,425 1,698,175
Cash, beginning of period 5,402,333 3,984,453
Cash, ending of period 18,141,758 5,682,628
Supplemental cash flow information:    
Cash paid for interest 135,220 791
Cash paid for taxes
Non-cash Investing and Financing transactions:    
Common stock issued and issuable on acquisition of intangible asset 43,535
Shares received as proceeds for the sale of Skincare 728,550
Series B preferred shares issues to settle accrued bonus liability 150,000
Consideration payable settled through termination of the agreement 894,151
Common stock issued to settle a portion of the ELOC $ 15,731,572
[1] Refer to Note 4 for disclosure of cash flows used in operating and investing activities of discontinued operations.